logo
Moses Lake launches resource info site

Moses Lake launches resource info site

Yahoo01-06-2025
May 31—MOSES LAKE — Moses Lake city officials are working on a new option for people looking for support services and help finding what they need. The "community resources page" is available on the city's web page, and city officials hope to print a brochure with the information eventually.
Lizabeth Murillo Busby, the city's housing and grants manager, said the resource page is part of the response to the decision to close the Open Doors Sleep Center. The facility will close June 30, when the state grant that funded most of its operation expires. Moses Lake City Council members opted not to renew the grant.
"The city, in the transition to close the sleep center, wanted to make sure we were highlighting and supporting the local agencies that are doing the work in the community. So, it's really a call to action for organizations in the community to input their information as they deem appropriate," Murillo Busby said.
Murillo Busby said the resource page is designed for organizations that provide services in Moses Lake. People have access to statewide resource lists and are encouraged to use them, she said, but this is targeted specifically at the help that is available locally.
"We want to make sure that we're targeting our audience in our community," she said.
It includes a link and QR code to a page where organizations can enter contact information and some information about the services and resources they provide. All entries are reviewed before they are added to the list.
The entries will be reviewed each March, Murillo Busby said.
Because it's a work in progress, the information will change over time, and people are encouraged to check on it regularly.
How best to use the information depends in part on the agency. Renew, the county's mental health agency, is listed in multiple categories, and Dayna Ruiz, Renew community relations manager, said it's best to call the listed phone number.
"The first stop, really, is just calling our front desk," Ruiz said.
Renew employees are trained to help people figure out who they need to talk to first.
"Just call our offices and share what their need is," she said.
People who are in a crisis might not even know what they need when they call, she said, but employees will help potential patients figure it out.
"It shouldn't be hard," Ruiz said. "People just need help."
There's also a county-based mental health crisis line, 800-852-2923, Ruiz said. It's available 24 hours per day, seven days a week. She said that number is not on the city's resource page yet, but it will be.
For the Moses Lake Community Coalition, director Megan Watson said the listed email address is the best way to guide people to the right coalition services. The coalition offers information and guidance for parents, a drop-in program for young people, and bags where families can lock up medication, among other services.
Coalition members are working on a website that should be ready by fall, Watson said, and when it is, the link will be added to the community resource page, if possible.
Works in progress being what they are, updated information will be available over time, as well as additional information. The local Goodwill agency offers a lot of different services from its office next to the thrift store in Moses Lake.
Goodwill has extensive resources, some of which people may not realize exist.
Jamie McDowall, onsite manager for Goodwill in Moses Lake, said two employees are assigned to help people who are facing substance abuse and mental health challenges find housing, and two others who help qualifying clients find jobs.
"We're pretty successful in helping people find housing and employment," she said. "We have a good crew here."
Some of its housing and employment programs are focused on people who are dealing with chronic homelessness, which is defined as being homeless in 12 months — not 12 consecutive months, just 12 months — during the last three years, McDowall said.
"We work pretty closely with people in addiction," she said.
Goodwill also helps people with financial management; employees help people who qualify through its program to help pay bills and manage the money they have left once that's done.
The page has a link and QR code for organizations that want to add their information to the listings. Submissions are reviewed after they're provided prior to being placed on the site.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Implantable Device Shows Promise for Preventing Hypoglycemia
Implantable Device Shows Promise for Preventing Hypoglycemia

Medscape

time25 minutes ago

  • Medscape

Implantable Device Shows Promise for Preventing Hypoglycemia

A new minimally invasive device, while still in development, could become a lifesaver for individuals with diabetes who experience hypoglycemia, according to researchers at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts. In a paper published in Nature Biomedical Engineering , Siddharth R. Krishnan, PhD, now an assistant professor of electrical engineering at Stanford University in Stanford, California, and colleagues at MIT described a wireless device implanted into diabetic mice that prevented hypoglycemia. The implant weighs < 2 g and is only 3 cm3 in size; it remains under the skin and releases a powdered version of glucagon automatically when a sensor detects low blood sugar. The researchers simulated hypoglycemia in the mice, and the release of the dry glucagon was triggered wirelessly. Measurements showed a rapid rise in blood glucose soon after the release, with a peak of 30 mg/dL after no more than 15 minutes. A second set of studies replicated conditions that often drive hypoglycemia, such as missed meals and automated infusions from insulin pumps. Similarly, the use of the wireless release of dry glucagon resulted in blood glucose concentrations above the threshold for hypoglycemia (average concentration of 80 mg/dL) within the first hour after the release. An area under the curve analysis over 30 minutes after release showed significant changes in the glucose group compared with the control group who received lactose. 'A Pathway to Emergency Rescue' 'Glucagon is widely administered as an emergency rescue drug for patients suffering acute hypoglycemia, particularly in the context of type 1 diabetes,' corresponding author Daniel Anderson, PhD, a professor at the Koch Institute for Integrative Cancer Research at MIT, told Medscape Medical News . Glucagon's short half-life and low stability in solution has made development of pump systems a challenge, he said. By contrast, 'Dry powder versions of glucagon offer long-term stability but are difficult to deliver,' he said. 'An implantable device that can respond to hypoglycemia and release dry powder glucagon potentially offers a pathway to emergency rescue from hypoglycemia events without the need for patient intervention,' Anderson said. The early impact of the dry power was unexpected, Anderson said. 'The glucagon in our system is a dry powder that we designed to dissolve directly in biofluid, and the timeline for this dissolution and subsequent availability of the drug in circulation was an open question when we started this project,' he noted. 'The fact that we saw biological activity within 5 minutes of drug release was an important result in this context, and not one that we predicted.' Although the device is not ready for human use, the size and longevity are key questions for adoption in clinical practice, Anderson told Medscape Medical News . 'We are working on miniaturizing the device, so it is compatible with minimally invasive insertion techniques, and with a sufficient number of doses to provide protection from acute hypoglycemia for multiple years,' he said. 'So far, we have validated the device in preclinical small animal models.' Simultaneously miniaturizing the system and optimizing the dose and longevity in large animal models are the next steps for research, he added. Unmet Need for Glycemic Control 'Hypoglycemia and fear of hypoglycemia remains major barriers to optimal glycemic control for those with diabetes,' said Andrew Kraftson, MD, a specialist in endocrinology and internal medicine at the University of Michigan, Ann Arbor, Michigan, in an interview. 'Glucagon emergency delivery devices have advanced and become more user friendly but will not work if not available or expired. Liquid glucagon presents numerous challenges and is not yet commercially available for dual hormone insulin pump use,' said Kraftson, who was not involved in the research. 'Dual hormone pumps that are being studied or have been approved in Europe are large/bulky, may require two CGM [continuous glucose monitoring] sensors, and may require glucagon to be refilled more frequently than insulin, so a nonliquid, implantable device could avoid some of the obstacles posed by liquid glucagon,' Kraftson noted. However, more research is needed on the logistics of human implementation of the glucagon delivery device tested in the current study, Kraftson told Medscape Medical News . Questions include how the device would be implanted; how many doses the reservoir would hold; and how often, on average, it would need to be changed, he said. Other factors include how cumbersome this device might be for humans, potential risks for irritation or infection, and options for manual delivery in the event of a malfunctioning CGM or signal challenges in device communication, he said. 'Ideally, glucagon use for patients with diabetes would expand beyond emergency rescue,' Kraftson added. 'Reducing or even holding insulin is sometimes insufficient to avoid hypoglycemia, particularly rapid onset.' 'Additionally, eating carbohydrates to prevent or treat hypoglycemia is not ideal given the risk of subsequent overcorrection/hyperglycemia and weight gain; therefore, more frequent, sensor/algorithm-based use of glucagon can more effectively achieve stable glucose levels and help avoid the 'rollercoaster,'' he said. The small size of the device in the current study may limit its ability to participate in the larger mission of glucose management but could certainly still play an important role in hypoglycemia reduction, he noted. This study was funded by the Leona M. and Harry B. Helmsley Charitable Trust, the National Institutes of Health, a JDRF postdoctoral fellowship, and the National Institute of Biomedical Imaging and Bioengineering. Anderson and several coauthors reported being inventors on a patent application relevant to the technology described in this study but had no other financial conflicts of interest.

Canada Issues Sweeping Updates for Obesity Pharmacotherapy
Canada Issues Sweeping Updates for Obesity Pharmacotherapy

Medscape

time25 minutes ago

  • Medscape

Canada Issues Sweeping Updates for Obesity Pharmacotherapy

TOPLINE: Canada has released an updated guideline on pharmacotherapy for obesity management in adults that includes six new and seven revised recommendations, reflecting the latest evidence through May 2025. METHODOLOGY: Researchers conducted a systematic literature review from January 2022 to July 2024, supplemented by relevant trials published through May 2025, to identify studies assessing the efficacy of pharmacotherapy for weight management. They also conducted 13 targeted searches on managing weight-related complications in 13 subpopulations with adiposity-related health issues, including cardiovascular disease, heart failure, prediabetes, obstructive sleep apnea, and osteoarthritis, among others. Primary care physicians, obesity medicine specialists, and people with lived experience of obesity provided feedback on the recommendations. TAKEAWAY: Measures of central adiposity, in addition to ethnicity-specific BMI and adiposity-related complications, should be used to guide the decision to initiate pharmacotherapy. Obesity pharmacotherapy should be used in conjunction with health behavior changes and individualized based on a person's specific health needs, values, and preferences. The recommendations include two new medications, tirzepatide and setmelanotide, that were not included in previous versions of the guideline, as well as new recommendations for obesity-related complications. The researchers recommend against the use of compounded medications or medications other than those approved for weight loss in people with excess adiposity. IN PRACTICE: Obesity pharmacotherapy 'is one of three pillars of treatment outlined in the full Canadian Adult Obesity Clinical Practice Guideline, with other pillars being behavioral and psychological and surgical approaches,' said the author in a press release. 'Obesity treatment should always be tailored to each person's specific health needs, values, and preferences.' SOURCE: The study, led by Sue Pedersen, MD, endocrinologist and obesity medicine specialist in Calgary and lead author of the guideline, was published online in the Canadian Medical Association Journal. LIMITATIONS: The guideline has limitations, in that it includes only medications currently approved in Canada, although other medications are approved for obesity management in other countries. Also, there are more than 200 health complications associated with obesity, and it was not feasible to search the literature for all of them. DISCLOSURES: Pedersen reported receiving grants for clinical trials from Novo Nordisk, AstraZeneca, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, Prometric, and Pfizer, and consulting fees from AstraZeneca, Bausch Health, Eli Lilly and Company, Novo Nordisk, Janssen, Boehringer Ingelheim, Sanofi, Merck, Abbott, Dexcom, HLS, Bayer, AbbVie, Roche, Amgen, and Pfizer. She has also received payment for medical education lectures and speakers bureaus from AstraZeneca, Bausch, Eli Lilly and Company, Novo Nordisk, Janssen Pharmaceuticals, Boehringer Ingelheim, Sanofi, Merck, Abbott, Dexcom, HLS, Bayer, and Pfizer, and has received travel support from AstraZeneca, Bausch, Eli Lilly and Company, Novo Nordisk, Boehringer Ingelheim, Abbott, and Dexcom. In addition, Pedersen reported participating on a data safety monitoring board for Regeneron. The other coauthors also report receiving fees from multiple commercial entities. These competing interests are included in the paper. Marilynn Larkin, MA, is an award-winning medical writer and editor whose work has appeared in numerous publications, including Medscape Medical News and its sister publication MDedge, The Lancet (where she was a contributing editor), and Reuters Health. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store